Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M7224 | RS 504393 | RS 504393 is a highly selective CCR2 chemokine receptor antagonist, with IC50 values of 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors, respectively. |
| M1971 | Maraviroc | Maraviroc (UK-427857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. |
| M56160 | AZD-4818 | AZD-4818 is a potent antagonist of chemokine CCR1. |
| M56159 | CP-481715 | CP-481715 is a potent, reversible and selective CCR1 antagonist with a Kd of 9.2 nM for human CCR1. |
| M56158 | cis-J-113863 | cis-J-113863 is a competitive chemokine receptor 1 (CCR1) antagonist, with IC50 values of 0.9 and 5.8 nM for human and mouse CCR1 receptors, respectively. |
| M56157 | IDOR-1117-2520 | IDOR-1117-2520 is a potent and selective antagonist of CCR6. |
| M56156 | trans-J-113863 | trans-J-113863 is a potent chemokine CCR1 and CCR3 receptor antagonist, and inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants with IC50 of 9.57 and 93.8 nM,respectively. |
| M55323 | JBH492 | JBH492 is a first-in-class (C-C chemokine receptor 7) CCR7-targeting ADC, comprising a humanized, Fc-silenced anti-CCR7 IgG1 antibody conjugated to maytansinoid microtubule inhibitor DM4 via a cleavable linker. |
| M54587 | IPG7236 | IPG7236 is a selective CCR8 antagonist that also exhibits significant tumor suppression in a mouse xenograft model of human breast cancer.IPG7236 can be used in cancer-related studies. |
| M53871 | CKLF1-C19 | CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). |
| M53231 | Met-RANTES (human) | Met-RANTES (human) is a partial antagonist of CCR5. |
| M50169 | IPG0521 | IPG0521 is a bifunctional antibody targeting CCR8, which can block CCR8 signaling with high intensity and weak ADCC function, and can effectively inhibit the growth of multiple tumor types in homologous and immunohumanized mouse models. |
| M50168 | IPGA05 | IPGA05 is a monoclonal antibody targeting CCR8 for tumor-related studies. |
| M50167 | PSB-114 | PSB-114 is an ADCC-enhanced targeted CCR8 humanized monoclonal antibody that removes tumor-associated CCR8-expressing Tregs and can be used in tumor-related studies. |
| M50166 | ZL-1218 | ZL-1218 is a novel anti-CCR8 antibody that can be used in studies related to solid tumors. |
| M50165 | HBM1022 | HBM1022 is an anti-CCR8 fully human monoclonal antibody for use in studies related to solid tumors. |
| M50164 | CM369 | CM369 is a potential first-of-its-kind (first-in-class) anti-chemokine receptor 8 (CCR8) monoclonal antibody that binds specifically to CCR8 on Treg and removes immunosuppressive Treg through ADCC action to relieve tumor suppression in the TME.CM369 can be used in studies related to advanced solid tumors. |
| M50163 | BGB-A3055 | BGB-A3055 is a monoclonal antibody targeting CCR8 for studies related to solid tumors. |
| M50162 | AMG-355 | AMG-355 is a monoclonal antibody targeting CCR8 for studies related to solid tumors. |
| M50161 | ABBV-514 | ABBV-514 is a CCR8 inhibitor that can be used in studies related to respiratory diseases and tumors. |
| M50160 | SRF-114 | SRF-114 is a human IgG1 anti-CCR8 monoclonal antibody that targets tumor Treg cells and induces antibody-dependent cell-mediated cytotoxicity (ADCC) through activation of NK cells, resulting in selective depletion of immunosuppressive tumor T regulatory cells (Tregs) while preserving peripheral Tregs. It can be used for tumor-related studies. |
| M50159 | S-531011 | S-531011 is a novel anti-human IgG1 antibody that exhibits in vitro antibody-dependent cytotoxicity against CCR8-expressing cells and neutralizing activity against the CCL1-CCR8 signaling pathway. It can be used in studies related to solid tumors. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
